BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 9935073)

  • 1. Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.
    Nikula TK; McDevitt MR; Finn RD; Wu C; Kozak RW; Garmestani K; Brechbiel MW; Curcio MJ; Pippin CG; Tiffany-Jones L; Geerlings MW; Apostolidis C; Molinet R; Geerlings MW; Gansow OA; Scheinberg DA
    J Nucl Med; 1999 Jan; 40(1):166-76. PubMed ID: 9935073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of alpha-emitting 213Bi-labeled antibody constructs for clinical use.
    McDevitt MR; Finn RD; Ma D; Larson SM; Scheinberg DA
    J Nucl Med; 1999 Oct; 40(10):1722-7. PubMed ID: 10520715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias.
    Jurcic JG; Caron PC; Nikula TK; Papadopoulos EB; Finn RD; Gansow OA; Miller WH; Geerlings MW; Warrell RP; Larson SM
    Cancer Res; 1995 Dec; 55(23 Suppl):5908s-5910s. PubMed ID: 7493368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer.
    McDevitt MR; Barendswaard E; Ma D; Lai L; Curcio MJ; Sgouros G; Ballangrud AM; Yang WH; Finn RD; Pellegrini V; Geerlings MW; Lee M; Brechbiel MW; Bander NH; Cordon-Cardo C; Scheinberg DA
    Cancer Res; 2000 Nov; 60(21):6095-100. PubMed ID: 11085533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells.
    Chen P; Wang J; Hope K; Jin L; Dick J; Cameron R; Brandwein J; Minden M; Reilly RM
    J Nucl Med; 2006 May; 47(5):827-36. PubMed ID: 16644753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.
    Sgouros G; Ballangrud AM; Jurcic JG; McDevitt MR; Humm JL; Erdi YE; Mehta BM; Finn RD; Larson SM; Scheinberg DA
    J Nucl Med; 1999 Nov; 40(11):1935-46. PubMed ID: 10565792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates.
    Milenic DE; Roselli M; Mirzadeh S; Pippin CG; Gansow OA; Colcher D; Brechbiel MW; Schlom J
    Cancer Biother Radiopharm; 2001 Apr; 16(2):133-46. PubMed ID: 11385960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice.
    Xu Y; Xu Q; Rosenblum MG; Scheinberg DA
    Leukemia; 1996 Feb; 10(2):321-6. PubMed ID: 8637241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
    Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
    Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
    Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
    Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
    J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.
    Hartmann F; Horak EM; Garmestani K; Wu C; Brechbiel MW; Kozak RW; Tso J; Kosteiny SA; Gansow OA; Nelson DL
    Cancer Res; 1994 Aug; 54(16):4362-70. PubMed ID: 8044783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195.
    Feldman E; Kalaycio M; Weiner G; Frankel S; Schulman P; Schwartzberg L; Jurcic J; Velez-Garcia E; Seiter K; Scheinberg D; Levitt D; Wedel N
    Leukemia; 2003 Feb; 17(2):314-8. PubMed ID: 12592328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
    Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
    J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efforts to control the errant products of a targeted in vivo generator.
    Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
    Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi.
    Kennel SJ; Boll R; Stabin M; Schuller HM; Mirzadeh S
    Br J Cancer; 1999 Apr; 80(1-2):175-84. PubMed ID: 10389994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
    Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia.
    Caron PC; Dumont L; Scheinberg DA
    Clin Cancer Res; 1998 Jun; 4(6):1421-8. PubMed ID: 9626458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.